Skip to main content
. 2015 Jun 10;8:65. doi: 10.1186/s13045-015-0163-z

Fig. 3.

Fig. 3

Overall survival of plasmablastic lymphoma patients showing a significant adverse impact of age >50 years (a) and lymph node involvement (b). Patients who presented with Ann Arbor stage III or IV disease had worse overall (c) and event-free survival (d) compared to patients who presented with stage I or II